Komen is the largest nonprofit funder of breast cancer research outside of the U.S. government, having invested more than $1.1 billion in research since its founding.

The research highlights the value of studying rare genetic diseases to uncover fundamental immunological mechanisms.

The project, called the Southeast Genomic Medicine Service, or SE-GEMS, will create a genomic eConsult service that allows clinicians to ask practical questions about genetic testing, test interpretation and next steps in care.

Genetic variants known to slow or speed metabolism of drugs for depression and anxiety disorders are very common.

A multi-institutional group has identified a “signature” of metabolic molecules associated with exercise-induced physiologic deficits that, when released into the bloodstream, signal heightened heart failure risk.

These findings highlight the critical need for tumor genomic testing for all patients to identify those with high-risk tumors, which occur more frequently in Black women, and which require more aggressive treatment to prevent recurrence.

Using Fitbits, researchers set out to discover how many additional steps patients need to reduce risks of chronic disease.